Kidney Precision Medicine Program (KPMP): Columbia AKI Recruitment Site

肾脏精准医学计划 (KPMP)：哥伦比亚 AKI 招聘网站

• 批准号: 10005325
• 负责人: JONATHAN M. BARASCH
• 金额: $ 30万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005325
• 关键词: Academic Medical Centers; Acute Renal Failure with Renal Papillary Necrosis; Address; Adult; Affect; African American; Area; Basic Science; Biological Markers; Biopsy; Biopsy Specimen; Blood; Blood Cells; Cardiovascular system; Cells; Chronic Kidney Failure; Clinical; Clinical Data; Clinical Sciences; Collaborations; Collection; Communities; Complement; Computerized Medical Record; Consensus; Consult; Core Biopsy; Coupled; Couples; Critical Pathways; Data; Data Collection; Diagnosis; Diagnostic; Electronic Health Record; Enrollment; Ensure; Epidemiology; Etiology; Event; Feces; Foundations; Functional disorder; Genetic; Genetic Markers; Genetic Processes; Goals; Gold; Histopathology; Hypertension; Injury; Injury to Kidney; Inpatients; Kidney; Kidney Diseases; LCN2 gene; Latino; Life; Longitudinal Studies; Longitudinal cohort; Measurement; Measures; Medical; Medical Genetics; Methods; Molecular; Morbidity - disease rate; Nephrology; Nephrons; New York; Outcome; Participant; Patients; Persons; Phase; Plasma; Protocols documentation; Renal Mass; Renal function; Research; Research Personnel; Resources; Response to stimulus physiology; Risk; Risk Factors; Role; Route; Saliva; Scientist; Sepsis; Serum; Services; Site; Solid; Standardization; Stimulus; Surveys; Techniques; Technology; Testing; Therapeutic; Time; Time trend; Tissues; To specify; Uncertainty; Universities; Urine; Visit; Work; base; cohort; diagnosis standard; effective therapy; expectation; experience; follow-up; genomic biomarker; genomic data; global health; interest; kidney biopsy; metropolitan; microbiome research; mortality; multidisciplinary; nephrotoxicity; novel; patient engagement; precision medicine; programs; prospective; recruit; renal damage; response; response to injury; targeted treatment

Project Summary (Abstract) Our project brings together an experienced multidisciplinary team of clinical and basic scientist investigators at Columbia University Medical Center with expertise in the fields of genetics, biomarkers, pathophysiology, histopathology, renal biopsies, and therapy for kidney diseases to meet the aims of the Kidney Precision Medicine Project (KPMP) Recruitment Site for acute kidney injury (AKI). Our primary objective in establishing this site is to apply precision medicine techniques to patient biospecimens, including renal biopsies, and longitudinal clinical data to understand the etiology of kidney damage and determine critical pathways that can be targeted for therapy. The KPMP will occur in two phases: the UG3 exploratory phase and the UH3 expansion phase. Leveraging our existing inpatient nephrology consult services, we will create a multiethnic cohort (including >50% enrollment of Latino and/or African-American subjects) of at least 200 patients with AKI over five years. In the exploratory phase of the project, we will enroll at least 50 subjects over two years and will standardize the collection of biospecimens from all study participants including blood, saliva, urine, stool, and renal biopsy samples collected specifically for research purposes. The biospecimens will be pre-processed for genetic, genomic, biomarker, and microbiome studies before the material is transferred to the KPMP Central Hub. To track patient progress and outcomes, a longitudinal study protocol will be used consisting of “dynamic” follow-up visits through electronic health records and yearly in-person visits. In addition, we will share all extracted electronic health record data, survey data, and longitudinal clinical data from follow-up visits from our participants with the larger KPMP initiative for collaborative purposes. In the expansion phase, we will increase the cohort size by enrolling an additional 150 patients over three years and use KPMP consortium- wide established protocols from the exploratory phase for biospecimen collection and longitudinal clinical data collection. We will perform proof-of-concept studies with the longitudinal cohort of 200 Columbia patients with AKI to determine a standard set of outcomes based on risk factors, known serum biomarkers, and genomic data. Lastly, we will work with local kidney foundation chapters and community engagement experts to ensure that the aims of the national KPMP are shared with the larger community so that participants understand the importance of this initiative and the long-term benefits of continued study involvement. We expect that this novel, tissue-based, mechanism-centered approach will challenge the traditional methods for diagnosing and treating AKI and will contribute to the overall goals of the national KPMP.

项目摘要（摘要） 我们的项目汇集了一个经验丰富的临床和基础科学家研究人员的经验丰富的跨学科团队 哥伦比亚大学医学中心具有遗传学，生物标志物，病理生理学领域的专业知识， 组织病理学，肾脏活检和肾脏疾病的治疗，以满足Kidsey精度的目标 急性肾脏损伤（AKI）的医学项目（KPMP）招募部位。我们建立的主要目标 该站点是将精确医学技术应用于患者的生物测量，包括肾脏活检和 纵向临床数据以了解肾脏损伤的病因，并确定可以的关键途径 针对治疗。 KPMP将分为两个阶段：UG3探索阶段和UH3 扩展阶段。利用我们现有的住院肾脏病咨询服务，我们将创建一个多民族 至少有200名AKI患者的队列（包括拉丁裔和/或非裔美国人的50％招生） 超过五年。在该项目的探索阶段，我们将在两年内至少注册50名受试者 将标准化所有研究参与者的生物测量，包括血液，唾液，尿液，粪便， 以及专门用于研究目的的肾脏活检样本。生物测量将进行预处理 对于材料转移到毕马威之前的遗传，基因组，生物标志物和微生物组研究 中央集线器。为了跟踪患者的进步和结果，将使用纵向研究方案 通过电子健康记录和年度面对面访问进行“动态”后续访问。此外，我们将 分享所有提取的电子健康记录数据，调查数据和后续访问的纵向临床数据 来自我们的毕马威会计师事务所的参与者来自我们的合作目的。在扩展阶段，我们将 通过在三年内增加150名患者，并使用毕马威（KPMP）联盟，增加了队列的大小 从探索性阶段进行生物测量和纵向临床数据的广泛建立方案 收藏。我们将对200名哥伦比亚患者的纵向队列进行概念证明研究 AKI根据风险因素，已知血清生物标志物和基因组确定一组标准的结果集 数据。最后，我们将与当地肾脏基金会章节和社区参与专家合作，以确保 国家毕马威（National KPMP）的目标与较大的社区共享，以便参与者了解 该计划的重要性以及继续研究的长期益处。我们期望这 新颖的，基于组织，以机制为中心的方法将挑战传统的诊断方法 治疗AKI，并将为国家毕马威（National KPMP）的整体目标做出贡献。